New York, July 22, 2026
LB Pharmaceuticals announced that it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial evaluating LB-102 for the treatment of schizophrenia during the first half of 2027, several months earlier than previously projected. The updated timeline follows stronger-than-expected patient enrollment in the ongoing multicenter study, which is enrolling approximately 460 patients across 25 clinical sites in the United States. Based on current enrollment trends, the company also plans to schedule a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA) during the second half of 2027. The accelerated development timeline marks an important milestone for LB-102, an investigational once-daily oral therapy that the company believes could become the first benzamide antipsychotic approved in the United States for neuropsychiatric disorders.
Rapid Enrollment Accelerates Pivotal Phase 3 Development
The NOVA-2 study is a randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of LB-102 in adults with schizophrenia. According to Chief Executive Officer Heather Turner, enrollment has progressed faster than anticipated, reflecting both efficient execution by clinical investigators and strong interest in the investigational therapy. As a result, LB Pharmaceuticals now expects to deliver pivotal topline data during the first half of 2027, ahead of its previous guidance targeting the second half of the year. Following the release of those results, the company intends to engage with the FDA through a pre-NDA meeting to discuss the regulatory pathway toward a potential marketing application. LB Pharmaceuticals also stated that its current financial position is expected to support operations through the second quarter of 2029, providing sufficient resources to complete several planned clinical milestones.
LB-102 Demonstrates Encouraging Clinical Profile
LB-102 is a novel, once-daily, orally administered small molecule developed as a methylated derivative of amisulpride, a well-established antipsychotic used in several countries outside the United States. The investigational therapy acts as a selective antagonist of dopamine D2, D3, and serotonin 5HT-7 receptors, while minimizing off-target receptor activity that can contribute to unwanted side effects. Earlier in 2025, the company reported positive Phase 2 clinical results in patients with acute schizophrenia, where LB-102 demonstrated statistically significant improvements compared with placebo across all dose levels evaluated. Investigators also observed rapid clinical improvement beginning in the first week of treatment, sustained efficacy throughout the study, low rates of extrapyramidal symptoms including akathisia, minimal sedation, limited gastrointestinal side effects, and encouraging effects on negative symptoms and cognitive performance. These findings support the continued advancement of LB-102 into pivotal clinical testing.
Advertisement
Broad Neuropsychiatric Development Strategy Continues
Beyond the ongoing Phase 3 NOVA-2 schizophrenia trial, LB Pharmaceuticals is expanding the clinical development of LB-102 across multiple neuropsychiatric disorders. The company expects topline results from the Phase 2 ILLUMINATE-1 trial evaluating LB-102 in bipolar I depression during the first quarter of 2028, while a Phase 2 study investigating the therapy as an adjunctive treatment for major depressive disorder (MDD) is expected to generate topline data in the first half of 2029. Additional future development opportunities include predominantly negative symptoms of schizophrenia, Alzheimer’s disease-related psychosis and agitation, and other neuropsychiatric conditions. With accelerated enrollment shortening the timeline for its pivotal schizophrenia program, LB Pharmaceuticals continues to strengthen the clinical and regulatory pathway for LB-102, positioning the investigational therapy as a potential new treatment option for patients living with serious psychiatric illnesses.
Source: LB Pharmaceuticals press release
